BAYER SAYS SCHERING OFFER UNCHANGED DESPITE RECENT DISAPPOINTMENTS

Bayer AG has informed Schering AG that its takeover offer remains unchanged despite the recall of a Ultravist product and the disappointing sargramostim clinical trial results.
Pharmaceutical Business Review